Linden Thomas Advisory Services LLC Buys 169 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Linden Thomas Advisory Services LLC boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 7,436 shares of the company’s stock after purchasing an additional 169 shares during the quarter. Linden Thomas Advisory Services LLC’s holdings in IDEXX Laboratories were worth $3,074,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. FSA Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the third quarter valued at approximately $25,000. E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of IDEXX Laboratories by 5,700.0% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after purchasing an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories in the fourth quarter worth approximately $31,000. Mowery & Schoenfeld Wealth Management LLC grew its position in IDEXX Laboratories by 750.0% in the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares during the period. Finally, Strategic Investment Solutions Inc. IL bought a new position in shares of IDEXX Laboratories during the 2nd quarter valued at $36,000. 87.84% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the transaction, the director now directly owns 905 shares of the company’s stock, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Trading Up 0.7 %

IDEXX Laboratories stock opened at $435.33 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The firm’s 50 day moving average price is $423.74 and its 200-day moving average price is $456.35. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.42 and a quick ratio of 1.03. The stock has a market cap of $35.65 billion, a P/E ratio of 41.98, a PEG ratio of 3.63 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million for the quarter, compared to the consensus estimate of $980.32 million. During the same period in the previous year, the firm posted $2.53 EPS. IDEXX Laboratories’s revenue for the quarter was up 6.6% compared to the same quarter last year. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on IDXX. Barclays reduced their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research report on Monday, November 4th. Piper Sandler reissued a “neutral” rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Leerink Partners began coverage on shares of IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price for the company. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, November 28th. Finally, Leerink Partnrs upgraded shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $523.86.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.